Results from an international phase III study of patients with advanced colorectal cancer, a disease which is especially difficult to treat once initial therapy ceases to be effective, point towards a more promising second-line treatment strategy for these patients by combining the targeted drug ramucirumab with standard chemotherapy.
The data, also selected for the official press program by the meeting’s co-sponsors, will be presented by Josep Tabernero, Director of the Vall d´Hebron Institute of Oncology (VHIO), at the forthcoming Gastrointestinal Cancers Symposium 2015, January 15 – 17, San Francisco, California.
To view ASCO´s press release now and find out more please visit: http://www.asco.org/press-center/second-line-ramucirumab-added-standard-chemotherapy-delays-disease-progression-extends.
For any additional information please contact: Amanda Wren, Communication Manager, Vall d´Hebron Institute of Oncology (VHIO), Tel. +34 695 207 886, Email: email@example.com.